InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

Reuters

2025/11/10

InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582765498"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582765498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582765498?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582765498","market":"fut","top_or_hot":-1,"title":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbGbyMg:1","article_id":"2582765498","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582765498","pubTimestamp":1762778223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa  and chronic spontaneous urticaria . The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score  and improvements in the Urticaria Control Test . InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IFRX":"InflaRx N.V."},"translate_title":"InflaRx报告INF904在HS和CSU中的阳性2a期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":0.9},"content_text":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    \n\nInflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}